US EditionJ&J's first-quarter profit beats estimates even as Stelara sales disappoint
- On Tuesday, April 14, 2026, Johnson & Johnson reported first-quarter revenue of $24.1 billion, surpassing expectations, while raising its full-year 2026 sales outlook and declaring a 3% dividend increase to $1.34 per share.
- Cancer therapy Darzalex and psoriasis treatment Tremfya drove significant growth, offsetting a steep 60% revenue decline in blockbuster autoimmune drug Stelara as biosimilar competition intensified.
- Adjusted earnings per share reached $2.70, surpassing the consensus estimate of $2.66, while medical technology business revenue rose 7.7% to $8.6 billion, meeting analyst expectations.
- Johnson & Johnson announced a $1 billion investment in a Pennsylvania-based cell therapy manufacturing facility, signaling long-term capacity expansion to support future growth.
- With its 64th consecutive annual dividend increase, Johnson & Johnson offers a 3.2% yield, nearly double the 1.8% healthcare sector average, sustaining structural appeal for income investors.
15 Articles
15 Articles
Yuhan Corporation’s Leclaza, J&J’s Key Anticancer Drug, Sales of Combination Therapy Hit Fivefold in Two Years; J&J Announces Q1 Earnings, Librivant + Leclaza Sales Up 82% Year-on-Year. The lung cancer combination therapy developed by U.S. pharmaceutical company Johnson & Johnson (J&J) and Yuhan Corporation is marking a new chapter in the history of K-new drugs with rapid sales growth in the global market.
Johnson and Johnson Raises Dividend for 64th Consecutive Year
The post Johnson and Johnson Raises Dividend for 64th Consecutive Year appeared first on 24/7 Wall St.. Quick Read Johnson & Johnson (JNJ) raised its quarterly dividend to $1.34 per share, a 3% increase from the prior $1.30 payout. Johnson & Johnson now offers a 3.2% yield, nearly double the 1.8% healthcare sector average, attracting income-focused investors. The company achieved its 64th consecutive annual dividend increase, demonstrating i…
Johnson & Johnson Q1 Performance: Cancer Drug Revenue Grows, Free Cash Flow Falls, Hikes Dividend
Johnson & Johnson (NYSE:JNJ) on Tuesday reported a first-quarter 2025 adjusted earnings of $2.70 per share, down 2.5% year over year, beating the consensus of $2.67. The U.S. healthcare giant reported sales of $24.06 billion, up 9.9% year over year and beating the consensus of $23.63 billion. Operational growth was 6.4%, and adjusted operational growth was 5.3%. Innovative Medicine Growth Driven By Oncology And Neuroscience Innovative Medicine s…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
